Joe Bolen, chief executive officer of Orna Therapeutics, said, “At Orna, we believe our circular RNA technology paired with our best-in-class LNP delivery platform have the potential to unlock in vivo CAR-T therapies for patients across a wide range of B cell-driven autoimmune diseases. We are excited to join forces with Lilly, an industry leader in the development of patient-centric therapeutics to realize the full potential of these technologies.”
Last week, Eli Lilly reported revenues of $19.3 billion for the fourth quarter, representing a 43% year-over-year increase. Driven by the strong top-line growth, adjusted earnings jumped 42% from last year to $7.54 per share in Q4.